Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonsurf in Metastatic or Locally Advanced Pancreatic Adenocarcinoma
NCT02921737Phase 2Terminated
- Sponsor
- University of Florida
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in pancreatic adenocarcinoma (PDAC), sponsored by University of Florida. Primary endpoint: Progression-Free Survival at 54 weeks. Started Nov 2017; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02921737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921737.